Capital Performance Advisors LLP Allogene Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 41 shares of ALLO stock, worth $111. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41Holding current value
$111% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
174Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$50.9 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$44.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$22.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$20.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$18.8 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $391M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...